CAMBRIDGE, Mass., Oct. 31 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals
Incorporated (Nasdaq: VRTX) announced today that N. Anthony Coles, M.D., has
resigned his position with the Company effective November 1, 2005. Dr. Coles
joined Vertex in 2002 and most recently held the title of Senior Vice
President, Commercial Operations. Dr. Coles has accepted a senior executive-
level position with another life sciences company. With the departure of Dr.
Coles, the strategic marketing areas formerly reporting to Dr. Coles will form
Vertex's Commercial Development function and will now report to John Alam,
M.D., Senior Vice President, Drug Evaluation and Approval. Vertex is currently
in advanced discussions with a number of potential candidates for the position
to head its Commercial Development function, reporting to Dr. Alam.
"Tony has been an integral part of the business during his tenure at our
Company, as Vertex has advanced key pharmaceutical products toward
commercialization," said Joshua Boger, Ph.D., Chairman, President and CEO of
Vertex. "We appreciate his contributions to our business and wish him well in
his future endeavors."
About Vertex
Vertex Pharmaceuticals Incorporated is a global biotechnology company
committed to the discovery and development of breakthrough small molecule
drugs for serious diseases. The Company's strategy is to commercialize its
products both independently and in collaboration with major pharmaceutical
companies. Vertex's product pipeline is principally focused on viral
diseases, inflammation, autoimmune diseases and cancer. Vertex co-promotes
the HIV protease inhibitor, Lexiva, with GlaxoSmithKline.
Lexiva is a registered trademark of the GlaxoSmithKline group of
companies.
Vertex's press releases are available at http://www.vrtx.com.
Vertex Safe Harbor Statement
This press release may contain forward-looking statements. While
management makes its best efforts to be accurate in making forward-looking
statements, such statements are subject to risks and uncertainties that could
cause Vertex's actual results to vary materially. These risks and
uncertainties include those risks listed under Risk Factors in Vertex's form
10-K filed with the Securities and Exchange Commission on March 16, 2005.
Vertex Contacts:
Michael Partridge, Director, Corporate Communications, (617) 444-6108
Zachry Barber, Media Relations Specialist, (617) 444-6470
Lora Pike, Manager, Investor Relations, (617) 444-6755
SOURCE Vertex Pharmaceuticals Incorporated
 back to top
Related links:
http://www.vrtx.com
Company News On-Call:
http://www.prnewswire.com/comp/938395.html
CONTACT:
Michael Partridge, Director, Corporate
Communications, +1-617-444-6108, or Zachry Barber, Media
Relations Specialist, +1-617-444-6470, or Lora Pike, Manager,
Investor Relations, +1-617-444-6755
|
